Find out now if you qualify. Time is limited to file a claim. You may be entitled to compensation. Fill out the form below to see if you qualify.
Sickle Cell Patients At Risk
Information submitted will be transmitted to a law firm. This communication is intended to be an attorney-client communication for purposes of evaluating your claim and will be kept confidential by the law firm. The communication does not create an attorney-client relationship and no relationship is formed until a fee agreement is signed by you and the law firm. I also have read and agree to your Privacy Policy
File Your Claim Now
April 2022: The MDL Paraquat class action judge will have a status conference on April 1st to review where the litigation is headed and how best to take the bellwether lawsuits forward for trial in November 2022. 44 new paraquat lawsuits have been added to the MDL in the last two weeks. At this pace, April 2022 will be the busiest month for new files yet. Last week, the parties filed their class-action bellwether picks with the Paraquat MDL judge. Those choices, however, have not been made public.
May 2022: In the last month, over 50 new cases have been added to the Paraquat Lawsuit Multidistrict Litigation (MDL). A group of six patients was recently selected by the Paraquat MDL court for the initial Paraquat Parkinson's disease bellwether trials. As a result, the first trial in November 2022 is approaching soon. The strategy is to select 16 paraquat claims from among the almost 1000 Parkinson's disease litigation claims filed. Following some limited fact discovery in these instances, paraquat attorneys on both sides submitted a preference list to the MDL court, ranking the 16 cases in order of priority. Attorneys for plaintiffs seek the finest facts for their clients, while defense attorneys want the worst. The judge whittled the list down to six Paraquat claims based on these rankings.
CLAIM UPDATES
We are here to listen and help answer all your questions. Contact us today for a Free Claim Review by filling out the form above.
Additional Studies
If you or a family member suffered from VOCs, stroke, organ damage, or death after taking Oxbryta, you may qualify to file a claim. Our experienced legal team will handle every aspect of the process, including gathering medical records and expert evaluations. We work on a contingency basis, meaning you pay nothing unless we win your case. Contact us today to find out if you qualify. Significant compensation may be available.
Seek Justice Today
Maryland Juvenile Detention
Abuse Claim Help
Jeff Brandow
Sexual Abuse
Claim Help
File Your Claim Now
The recent recall of OXBRYTA® has exposed new health risks facing patients with sickle cell disease. Originally prescribed to manage symptoms, OXBRYTA has now been linked to severe complications such as vaso-occlusive crises (VOCs) and, in some cases, death. Patients like you relied on this treatment but have instead suffered worsening health and mounting medical bills. Anyone that took OXBRYTA, we want to hear from you.
We are committed to helping sickle cell patients who were prescribed OXBRYTA. If you or a loved one took OXBRYTA at any time, you may be entitled to compensation for medical expenses, pain and suffering, lost wages, and more.
OXBRYTA was approved by the FDA in 2019 for adults and children aged 12 and older and later expanded to patients 4 years and older in 2021. Post-marketing clinical trials revealed that patients taking Oxbryta experienced a greater incidence of vaso-occlusive crises (VOCs) and fatalities compared to those on a placebo. One of the clinical trials involving 236 patients resulted in at least eight deaths among the particpants.
"Trust our experienced team to handle your claim with care and commitment. Contact us today for reliable legal support."
Our dedicated team will fight for your rights and compensation. Confidentiality, Safety, & Justice are our top priorities
How to Qualify for a Depo-Provera Claim:
Use of Depo-Provera
Diagnosis of Brain Tumor
Document Evidence
Submit The Form Above
Depo-Provera is an injectable birth control containing the synthetic hormone medroxyprogesterone acetate, is linked to an increased risk of meningioma, a rare brain tumor. This risk was not adequately disclosed to consumers or medical professionals. Studies, including those published in the Journal of the American Medical Association (JAMA), have shown that long-term use of Depo-Provera significantly raises the risk of developing meningiomas.
Claims against Pfizer, Inc., the drug’s manufacturer, alleges that the company knew or should have known about the increased risk of meningiomas—brain tumors that can cause severe neurological symptoms—especially with prolonged use. The claims state that Pfizer failed to adequately warn doctors and patients, rushed the drug to market without sufficient long-term studies, and prioritized profits over safety.
Due to the rising number of claims against Pfizer regarding Depo-Provera and brain tumors have been consolidated into multidistrict litigation (MDL) in federal court. Affected individuals may seek compensation for medical expenses, long-term care, and other damages, with the potential for federal court consolidation of cases.
OXBRYTA Recall Claims
Justice & Compensation - Start Here
It’s important to work closely with your healthcare provider on your treatment plan, but you should also explore your legal options. Anyone who was prescribed OXBRYTA and experienced complications such as worsening symptoms, increased VOCs, or other health issues. Contact us immediately for a free claim review.
VOCs are the most common complication of Oxbryta usage. Vaso-occlusive events block blood flow, which prevents oxygen from reaching tissues and organs. These events can result in organ damage, stroke, kidney failure, and even death.
Don’t wait—time may be limited. If you or a loved one took Oxbryta at any time, fill out the form above for a Free Claim Review.
You may have a claim if, after starting Oxbryta (voxelotor) for sickle‑cell disease, you or a loved one suffered any of the following:
Vaso‑occlusive crisis (VOC) – intense pain episodes, hospitalization
Stroke or other neurological injury
Organ failure (kidney, liver or multi‑organ)
Wrongful death believed linked to Oxbryta use
In September 2024, Pfizer issued a global voluntary recall of Oxbryta after post-marketing data and ongoing clinical trials indicated a disturbing trend: patients on Oxbryta were suffering from higher rates of VOCs and fatal complications. European regulators took similar action by suspending the drug's marketing authorization, citing the potential for Oxbryta to worsen patient outcomes rather than improve them. These actions have raised serious concerns about the drug’s safety profile and whether patients were adequately warned of the risks.
